BioSpace News Archive

Bellerophon Therapeutics, Inc. today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD).

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults.

Grifols announced it has launched its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of alpha1-antitrypsin deficiency.

Comera Life Sciences Holdings, Inc. today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

Femasys Inc. today announced that the Company’s management team will be attending the annual American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM) being held May 19-21, 2023 in Baltimore, Maryland.

ChromaDex Corp. today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference.

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced it has completed enrollment of its Phase 2b EMBARK study for pediatric patients with biliary atresia, the most common indication for pediatric liver transplant.

Jaguar Health, Inc. under its Jaguar Animal Health tradename for the veterinary market, announced that Canalevia-CA1, the company’s U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is now available on Chewy, a trusted destination for pet parents and partners everywhere.

Olema Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK4/6 inhibitor, for the treatment of ER+/HER2- metastatic breast cancer.